Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Day One Biopharmaceuticals (DAWN) Equity Average (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Equity Average for 4 consecutive years, with $446.0 million as the latest value for Q4 2025.

  • For Q4 2025, Equity Average fell 15.7% year-over-year to $446.0 million; the TTM value through Dec 2025 reached $446.0 million, down 15.7%, while the annual FY2025 figure was $472.0 million, 11.14% up from the prior year.
  • Equity Average was $446.0 million for Q4 2025 at Day One Biopharmaceuticals, down from $455.9 million in the prior quarter.
  • The five-year high for Equity Average was $529.1 million in Q4 2024, with the low at $301.8 million in Q2 2024.
  • Historically, Equity Average has averaged $396.8 million across 4 years, with a median of $376.9 million in 2022.
  • The largest annual shift saw Equity Average decreased 16.92% in 2024 before it surged 55.81% in 2025.
  • Over 4 years, Equity Average stood at $347.6 million in 2022, then increased by 5.91% to $368.1 million in 2023, then soared by 43.75% to $529.1 million in 2024, then decreased by 15.7% to $446.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $446.0 million in Q4 2025, $455.9 million in Q3 2025, and $470.2 million in Q2 2025.